Table 1 Patient characteristics... | American Society of Hematology

Table 1

Patient characteristics

Variables	Total		CY/TBI		HDCA/CY/TBI		P
Variables	n = 929	%	n = 312	%	n = 617	%	P
Sex
Male	505	54.4	171	54.8	334	54.1
Female	424	45.6	141	45.2	283	45.9	.85
Age
Median, years (range)	40 (16-66)		40.5 (16-66)		40 (16-64)		.58
<50	736	79.2	238	76.3	498	80.7
≥50	193	20.8	74	23.7	119	19.3	.12
PS
0-1	774	83.3	243	77.8	531	86.0
2-4	80	8.6	32	10.3	48	7.8
Unknown	75	8.1	37	11.9	38	6.2	<.01*
Hematopoietic cell transplant commodity index
0-2	513	55.2	165	52.8	348	56.4
3-29	64	6.9	17	5.5	47	7.6
Unknown	352	37.9	130	41.7	222	36.0	.16
CMV serostatus
Negative	157	16.9	59	18.9	98	15.9
Positive	689	74.2	213	68.3	476	77.1
Unknown	83	8.9	40	12.8	43	7.0	<.01*
Disease
AML	801	86.2	277	88.8	524	84.9
MDS	128	13.8	35	11.2	93	15.1	.11
Disease risk
Standard	407	43.8	157	50.3	250	40.5
High	522	56.2	155	49.7	367	59.5	<.01*
In AML
Standard	371	46.3	148	53.4	223	42.6
High	430	53.7	129	46.6	301	57.4	<.01*
In MDS
Standard	36	28.1	9	25.7	27	29.0
High	92	71.9	26	74.3	66	71.0	.71
Pretransplant therapy period
Median, days	218		202.5		231		.12
≤200	423	45.5	155	49.7	268	43.4
≥201	506	54.5	157	50.3	349	56.6	.07
HLA mismatch
Matched	37	4.0	18	5.8	19	3.1
Mismatched	892	96.0	294	94.2	598	96.9	.05*
Sex mismatch
Matched	353	38.0	127	40.7	226	36.6
Male to female	163	17.6	50	16.0	113	18.3
Female to male	181	19.5	64	20.5	117	19.0
Unknown	232	24.9	71	22.8	161	26.1	.44
ABO mismatch
Matched	312	33.6	87	27.9	225	36.4
Minor	254	27.3	102	32.6	152	24.6
Major	212	22.8	71	22.8	141	22.9
Both	151	16.3	52	16.7	99	16.1	.02*
NCC, 10⁷cells/kg
Median	3.03		3.00		3.10		.50
GVHD prophylaxis
CyA based	548	59.0	159	51.0	389	63.0
Tac based	381	41.0	153	49.0	228	37.0	<.01*
Year of CBT
2000-2007	424	45.6	154	49.4	270	43.8
2008-2012	505	54.4	158	50.6	347	56.2	.11
Follow-up period
Median (range)	1276.5 (37-4,911)		1084 (82-4007)		1328 (37-4911)		.09

Variables	Total		CY/TBI		HDCA/CY/TBI		P
Variables	n = 929	%	n = 312	%	n = 617	%	P
Sex
Male	505	54.4	171	54.8	334	54.1
Female	424	45.6	141	45.2	283	45.9	.85
Age
Median, years (range)	40 (16-66)		40.5 (16-66)		40 (16-64)		.58
<50	736	79.2	238	76.3	498	80.7
≥50	193	20.8	74	23.7	119	19.3	.12
PS
0-1	774	83.3	243	77.8	531	86.0
2-4	80	8.6	32	10.3	48	7.8
Unknown	75	8.1	37	11.9	38	6.2	<.01*
Hematopoietic cell transplant commodity index
0-2	513	55.2	165	52.8	348	56.4
3-29	64	6.9	17	5.5	47	7.6
Unknown	352	37.9	130	41.7	222	36.0	.16
CMV serostatus
Negative	157	16.9	59	18.9	98	15.9
Positive	689	74.2	213	68.3	476	77.1
Unknown	83	8.9	40	12.8	43	7.0	<.01*
Disease
AML	801	86.2	277	88.8	524	84.9
MDS	128	13.8	35	11.2	93	15.1	.11
Disease risk
Standard	407	43.8	157	50.3	250	40.5
High	522	56.2	155	49.7	367	59.5	<.01*
In AML
Standard	371	46.3	148	53.4	223	42.6
High	430	53.7	129	46.6	301	57.4	<.01*
In MDS
Standard	36	28.1	9	25.7	27	29.0
High	92	71.9	26	74.3	66	71.0	.71
Pretransplant therapy period
Median, days	218		202.5		231		.12
≤200	423	45.5	155	49.7	268	43.4
≥201	506	54.5	157	50.3	349	56.6	.07
HLA mismatch
Matched	37	4.0	18	5.8	19	3.1
Mismatched	892	96.0	294	94.2	598	96.9	.05*
Sex mismatch
Matched	353	38.0	127	40.7	226	36.6
Male to female	163	17.6	50	16.0	113	18.3
Female to male	181	19.5	64	20.5	117	19.0
Unknown	232	24.9	71	22.8	161	26.1	.44
ABO mismatch
Matched	312	33.6	87	27.9	225	36.4
Minor	254	27.3	102	32.6	152	24.6
Major	212	22.8	71	22.8	141	22.9
Both	151	16.3	52	16.7	99	16.1	.02*
NCC, 10⁷cells/kg
Median	3.03		3.00		3.10		.50
GVHD prophylaxis
CyA based	548	59.0	159	51.0	389	63.0
Tac based	381	41.0	153	49.0	228	37.0	<.01*
Year of CBT
2000-2007	424	45.6	154	49.4	270	43.8
2008-2012	505	54.4	158	50.6	347	56.2	.11
Follow-up period
Median (range)	1276.5 (37-4,911)		1084 (82-4007)		1328 (37-4911)		.09

NCC, nuclear cell count; CyA, cyclosporine; Tac, tacrolimus.

Statistically significant.

View Large

This Feature Is Available To Subscribers Only